Archived documents

Documents past their public comment period for Healthcare & Public Health.

FDAOther

PSG_210745 - Draft Guidance on Apremilast

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_202971 - Draft Guidance on Aripiprazole

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_218643 - Draft Guidance on Articaine Hydrochloride

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_219208 - Draft Guidance on Atrasentan Hydrochloride

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_219616 - Draft Guidance on Avutometinib Potassium; Defactinib Hydrochloride

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_207921 - Draft Guidance on Beclomethasone Dipropionate

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_020911 - Draft Guidance on Beclomethasone Dipropionate

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_216579 - Draft Guidance on Budesonide; Formoterol Fumarate

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_021929 - Draft Guidance on Budesonide; Formoterol Fumarate Dihydrate

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_212122 - Draft Guidance on Budesonide; Formoterol Fumarate; Glycopyrrolate

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_209819 - Draft Guidance on Buprenorphine

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22
FDAOther

PSG_215499 - Draft Guidance on Cabotegravir

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 22